ISPC· Health Care› Diagnostics & Research

iSpecimen Inc.

Stage 4 · Declining · week 52

As of Oct 22, 2026, iSpecimen is in Stage 4, the downtrend phase, now in week 52 (since Oct 16, 2025). It closed at $0.83, 97.6% below its 52-week high and below its 200-day average, which is falling.

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More about the company

$0.83

-6.67% today

$2.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ISPC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 43w

S4 51w

S4 53w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 43w → S1 9w → S4 51w → S1 3w → S4 3w → S1 4w → S4 53w current

Total tracked: 166 weeks across 7 stage runs.

ISPC among Diagnostics & Research43rd of 44 by relative strength

All 44 →

Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CDNACareDx, Inc.	Stage 2 · wk 24	99	+27.3%
2	BDSXBiodesix, Inc.	Stage 2 · wk 18	98	−18.3%
3	ILMNIllumina, Inc.	Stage 2 · wk 24	97	+5.5%
4	GHGuardant Health, Inc.	Stage 2 · wk 21	97	−7.6%
5	NTRANatera, Inc.	Stage 2 · wk 20	96	+2.7%
6	CRLCharles River Laboratories International, Inc.	Stage 2 · wk 16	92	+22.5%
7	RVTYRevvity, Inc.	Stage 2 · wk 18	90	+10.7%
8	PSNLPersonalis, Inc.	Stage 2 · wk 17	90	−3.2%
…43	ISPCiSpecimen Inc.	Stage 4 · wk 52	4	−31.2%

vs 52W High

-97.6%

$0.83 lo$34.40 hi

97.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 52

1w13w26w

Week 52, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-84.0%

200 DMA: $5.21 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.08x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-31.2%

-57.7%

-87.1%

YTD

-92.7%

-97.5%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 52 · Vol 0.08x

2026-10-21S4

Wk 51 · Vol 0.08x

2026-10-20S4

Wk 51 · Vol 0.28x

2026-10-19S4

Wk 51 · Vol 1.01x

2026-10-16S4

Wk 51 · Vol 0.06x

2026-10-15S4

Wk 51 · Vol 0.12x

2026-10-14S4

Wk 50 · Vol 0.08x

2026-10-13S4

Wk 50 · Vol 0.08x

2026-10-12S4

Wk 50 · Vol 0.05x

2026-10-09S4

Wk 50 · Vol 0.09x

2026-10-08S4

Wk 50 · Vol 0.09x

2026-10-07S4

Wk 49 · Vol 0.06x

Moving averages & range

50 DMA

$1.40

200 DMA

$5.21

52W High

$34.40

52W Low

$0.83

5D Low

$0.83

Resistance levels (recent highs)

20d High

$1.26

60d High

$2.38

120d High

$5.93

250d High

$34.40

Next resistance

+51.3%

to 20d High

ROE

-968.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.7

iSpecimen: quick answers

What stage is iSpecimen in?

As of Oct 22, 2026, iSpecimen (ISPC) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 16, 2025 and is in week 52. What the four stages mean

Is iSpecimen in an uptrend?

No. iSpecimen is in a Stage 4 downtrend. It trades 84.0% below its 200-day average, which is falling.

How far is iSpecimen from its 52-week high?

iSpecimen closed at $0.83 on Oct 22, 2026, 97.6% below its 52-week high of $34.40. Its 52-week low is $0.83.

How has iSpecimen performed over the past year?

As of Oct 22, 2026, iSpecimen is down 97.5% over the past year and down 92.7% so far in 2026.

Which sector and industry is iSpecimen in?

iSpecimen is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.